PLK1 expression and KRAS mutations in colorectal cancer (CRC)

Authors:

Priya Jayachandran, Andrew Elliott, Francesca Battaglin, Emil Lou, Wu Zhang, Shivani Soni, Hiroyuki Arai, Jingyuan Wang, Joshua Millstein, Albert Lockhart, W. Michael Korn, Heinz-Josef Lenz

Conclusions: 

  • A lack of increased PLK1 expression suggests similar potential for PLK1 inhibitors in KRAS-MT tumors compared to KRAS-WT.
  • Among PLK1 expression groups, proportionate increases in dMMR/MSI-H, TMB, and other immune related markers suggest a potential response to immunotherapy in tumors with increased PLK1 expression.
  • Combining immunotherapy with a PLK1 inhibitor might be a synergistic approach to increase sensitivity in PLK1-overexpressing CRC regardless of KRAS status.

Download Publication